切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2022, Vol. 16 ›› Issue (05) : 472 -475. doi: 10.3877/cma.j.issn.1674-3253.2022.05.022

综述

肾癌伴静脉瘤栓的外科治疗进展
阿地力·克然木1, 瓦斯里江·瓦哈甫1, 邢念增1,()   
  1. 1. 100021 北京,国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院泌尿外科
  • 收稿日期:2021-08-23 出版日期:2022-10-01
  • 通信作者: 邢念增
  • 基金资助:
    国家自然科学基金面上项目(81772700,81972400)

Progress in surgical treatment of renal carcinoma with venous tumor thrombus

Kramu Adidly·1, Wahafu Valijiang1, Nianzeng Xing1()   

  • Received:2021-08-23 Published:2022-10-01
  • Corresponding author: Nianzeng Xing
引用本文:

阿地力·克然木, 瓦斯里江·瓦哈甫, 邢念增. 肾癌伴静脉瘤栓的外科治疗进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(05): 472-475.

Kramu Adidly·, Wahafu Valijiang, Nianzeng Xing. Progress in surgical treatment of renal carcinoma with venous tumor thrombus[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2022, 16(05): 472-475.

肾癌是常见的泌尿系肿瘤,根据国家癌症中心2020年12月发布的我国最新的癌症流行病学数据,2015年我国新发肾癌病例约为7.4万,世界人口标化发病率为3.56/10万;约有2.7万死亡病例,世界人口标化死亡率为1.21/10万[1]。肾癌伴静脉瘤栓是局部进展性肾癌的临床特点之一,包括侵及肾静脉及下腔静脉。局部进展期肾癌中约4%~10%合并下腔静脉癌栓[2]。过去很长一段时间肾癌合并静脉瘤栓由于风险大,预后差,多选择放弃手术及其他治疗。但随着医学技术的进步,尤其是手术设备、技术、影像手段、药物等的发展,以及多学科诊疗模式的推广,肾癌伴静脉瘤栓患者能够得到最优治疗,预后也得到了改善。

表1 2015~2020年腹腔镜下肾癌伴静脉瘤栓切除术的围手术期结果汇总
[1]
Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015[J]. J Natl Cancer Cent, 2021, 1(1): 2-11.
[2]
Blute ML, Leibovich BC, Lohse CM, et al. The mayo clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus[J]. BJU Int, 2004, 94(1): 33-41.
[3]
黄庆波, 彭程, 顾良友, 等. 肾肿瘤伴静脉瘤栓"301分级系统"及手术策略(附100例病例分析)[J]. 微创泌尿外科杂志, 2017, 6(6): 328-332.
[4]
张建忠, 田溪泉, 张军晖, 等. 3D腹腔镜下行肾根治性切除及下腔静脉瘤栓取出术l例[J/CD].中华腔镜泌尿外科杂志(电子版), 2015, 9(3): 215-216.
[5]
张旭, 王保军, 马鑫, 等. 机器人辅助腹腔镜下根治性肾切除联合下腔静脉瘤栓取出术的临床研究[J]. 中华泌尿外科杂志, 2015, 36(5): 321-324.
[6]
Beksac AT, Shah QN, Paulucci DJ, et al. Trends and outcomes in contemporary management renal cell carcinoma and vena cava thrombus[J]. Urol Oncol, 2019, 37(9): 576.e517-576.e523.
[7]
Shao P, Li J, Qin C, et al. Laparoscopic radical nephrectomy and inferior vena cava thrombectomy in the treatment of renal cell carcinoma[J]. Eur Urol, 2015, 68(1): 115-122.
[8]
Gill IS, Metcalfe C, Abreu A, et al. Robotic level iii inferior vena cava tumor thrombectomy: initial series[J]. J Urol, 2015, 194(4): 929-938.
[9]
Wang B, Li H, Ma X, et al. Robot-assisted Laparoscopic Inferior Vena Cava Thrombectomy: Different Sides Require Different Techniques[J]. Eur Urol, 2016, 69(6): 1112-1119.
[10]
Abaza R, Eun DD, Gallucci M, et al. Robotic surgery for renal cell carcinoma with vena caval tumor thrombus[J]. Eur Urol Focus, 2016, 2(6): 601-607.
[11]
Chopra S, Simone G, Metcalfe C, et al. Robot-assisted level ii-iii inferior vena cava tumor thrombectomy: step-by-step technique and 1-year outcomes[J]. Eur Urol, 2017, 72(2): 267-274.
[12]
Wang B, Li H, Huang Q, et al. Robot-assisted retrohepatic inferior vena cava thrombectomy: first or second porta hepatis as an important boundary landmark[J]. Eur Urol, 2018, 74(4): 512-520.
[13]
Tohi Y, Makita N, Suzuki I, et al. En bloc laparoscopic radical nephrectomy with inferior vena cava thrombectomy: a single-institution experience[J]. Int J Urol, 2019, 26(3): 363-368.
[14]
Tian X, Hong P, Liu Z, et al. En bloc retroperitoneal laparoscopic radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma with level 0 to II venous tumor thrombus: A single-center experience[J]. Cancer, 2020, 126 Suppl 9: 2073-2078.
[15]
Wang B, Huang Q, Liu K, et al. Robot-assisted level iii-iv inferior vena cava thrombectomy: initial series with step-by-step procedures and 1-yr outcomes[J]. Eur Urol, 2020, 78(1): 77-86.
[16]
Psutka SP, Leibovich BC. Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma[J]. Ther Adv Urol, 2015, 7(4): 216-229.
[17]
Aghazadeh MA, Goh AC. Robotic left-sided level ii caval thrombectomy and nephrectomy using a novel supine, single-dock approach: primary description[J]. Urology, 2018, 112: 205-208.
[18]
Shi T, Huang Q, Liu K, et al. Robot-assisted cavectomy versus thrombectomy for level ii inferior vena cava thrombus: decision-making scheme and multi-institutional analysis[J]. Eur Urol, 2020, 78(4): 592-602.
[19]
Zhuo L, Guodong Z, Xun Z, et al. A modified surgical technique of shortening renal ischemia time in left renal cancer patients with Mayo level II-IV tumor thrombus[J]. BMC Surg, 2020, 20(1): 120.
[20]
Abaza R, Shabsigh A, Castle E, et al. Multi-institutional experience with robotic nephrectomy with inferior vena cava tumor thrombectomy[J]. J Urol, 2016, 195(4 Pt 1): 865-871.
[21]
Palma-Zamora I, Dalela D, Barod R, et al. Initial robotic assistance in the surgical management of renal cell carcinoma with level 4 cavoatrial thrombus[J]. J Robot Surg, 2018, 12(4): 737-740.
[22]
Shen D, Du S, Huang Q, et al. A modified sequential vascular control strategy in robot-assisted level III-IV inferior vena cava thrombectomy: initial series mimicking the open 'milking' technique principle[J]. BJU Int, 2020, 126(4): 447-456.
[23]
Bhat A, Nahar B, Venkatramani V, et al. Metastatic renal cell carcinoma with level iv thrombus: contemporary management with complete response to neoadjuvant targeted therapy[J]. Case Rep Urol, 2019, 2019: 7102504.
[24]
Al Diab A, Hirmas N, Almousa A, et al. Inferior vena cava involvement in children with Wilms tumor[J]. Pediatr Surg Int, 2017, 33(5): 569-573.
[25]
Elayadi M, Hammad M, Sallam K, et al. Management and outcome of pediatric Wilms tumor with malignant inferior Vena cava thrombus: largest cohort of single-center experience[J]. Int J Clin Oncol, 2020, 25(7): 1425-1431.
[26]
Margulis V, Freifeld Y, Pop LM, et al. Neoadjuvant sabr for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2021, 110(4):1135-1142.
[27]
Jurado A, Romeo A, Gueglio G, et al. Current trends in management of renal cell carcinoma with venous thrombus extension[J]. Curr Urol Rep, 2021, 22(4): 23.
[28]
Campi R, Tellini R, Sessa F, et al. Techniques and outcomes of minimally-invasive surgery for nonmetastatic renal cell carcinoma with inferior vena cava thrombosis: a systematic review of the literature[J]. Minerva Urol Nefrol, 2019, 71(4): 339-358.
[29]
Woo S, Suh CH, Kim SY, et al. Diagnostic performance of dwi for differentiating high- from low-grade clear cell renal cell carcinoma: a systematic review and meta-analysis[J]. AJR Am J Roentgenol, 2017, 209(6): W374-W381.
[1] 李秋洋, 赵萍, 李静波, 宋禄达, 朱嘉宁, 姜波, 罗渝昆. 高帧频超声造影对小肾透明细胞癌假包膜的评价价值[J/OL]. 中华医学超声杂志(电子版), 2023, 20(11): 1114-1118.
[2] 熊鹰, 林敬莱, 白奇, 郭剑明, 王烁. 肾癌自动化病理诊断:AI离临床还有多远?[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 535-540.
[3] 吴伟宙, 王琼仁, 詹雄宇, 郑明星, 李亚县. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——左肾肉瘤样癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 525-529.
[4] 李飞, 郑灶松, 吴芃, 谭万龙. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——延胡索酸水合酶缺陷型晚期肾细胞癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 410-414.
[5] 周慧宇, 吕定阳, 双卫兵. 联合系统性免疫炎症指数和预后营养指数预测腹腔镜肾切除术后肾癌患者的预后[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 225-231.
[6] 朱显钟, 李金雨, 于忠英, 温路生. 淋巴结平均直径与无淋巴结转移肾癌病理特征及预后关系研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 146-151.
[7] 加素尔·巴吐尔, 徐铭泽, 唐钵, 曾浩, 苏力坦·乌斯曼, 陈羽. 广东省医学会泌尿外科疑难病例多学科会诊(第14期)——左肾原发罕见恶性肿瘤并全身多处转移[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(01): 110-113.
[8] 戴志红, 刘志宇. 囊性肾癌肾部分切除术的实践与思考 [J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 423-423.
[9] 杨春亭, 毛云华, 罗云, 刘博皓. 孤立肾合并肾混合性上皮间质肿瘤一例报告并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 407-409.
[10] 努尔艾力·排尔哈提, 展昭兴, 王令令, 张古田, 朱新胜. 肾癌合并静脉癌栓的诊疗进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(05): 459-462.
[11] 张瑞敏, 于杰, 于晓玲. 早期肾细胞癌的影像引导消融治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(04): 381-384.
[12] 刘和谦, 陶凌松, 王家伟, 陈弋生, 邹滨, 沈旭东. 肾蒂血管处理新策略对缩短后腹腔镜下肾癌根治术学习曲线的正面作用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(02): 147-150.
[13] 佟凯军, 刘大振, 汤坤龙, 杨长海. 后腹腔镜下肾部分切除与根治性肾切除治疗T1期肾癌的疗效分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(02): 142-146.
[14] 王宝, 吴大鹏, 段中琪, 顾浩.
后腹腔镜肾部分切除术与肾癌根治术治疗复杂性T1b期肾肿瘤的比较 
#br#
[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2022, 16(02): 137-141.
[15] 刘晓梅, 张露, 刘旭, 梁蝶. 巨噬细胞迁移抑制因子靶向miR-127-3p对人肾癌细胞生物学行为的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 76-83.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?